Table 2.
Preclinical Studies Demonstrating the Importance of HO-1 in Disease
Strain | Model | Phenotype | Refs |
---|---|---|---|
| |||
Hmox1−/− | Vascular Injury | Increased intimal hyperplasia | 29 |
Pulmonary Ischemia/Reperfusion | Repression of fibrinolysis | 30 | |
Hypoxia | Increased myocardial infarction, Right ventricular dilation | 31 | |
| |||
Hmox1TG (Cardiac) | Ischemia/Reperfusion | Protection from I/R injury | 32 |
Reduction of cardiomyocyte apoptosis | 33 | ||
Hmox1TG (Cardiac, Inducible) | Cardiotoxicity (Cre-recombinase) | Protection from cardiotoxicity | 34 |
| |||
Hmox1TG (Pulmonary) | Hypoxia-induced pulmonary hypertension | Reduced symptoms of hypertension | 35 |
Anti-inflammatory protection | 36 | ||
| |||
Hmox1TG (Keratinocyte) | Skin lesions | Improved wound healing and vascularization | 37 |